Bristol Myers Bags RayzeBio in $4.1B Cancer Fight Pact
Pharma giant Bristol Myers Squibb acquires RayzeBio for $4.1 billion, expanding its presence in the oncology sector and strengthening its ...
- Latest
- Trending
Pharma giant Bristol Myers Squibb acquires RayzeBio for $4.1 billion, expanding its presence in the oncology sector and strengthening its ...
Analysts predict AI-integrated iPhones could boost Apple's stock and sales, potentially leading to more device replacements and revenue opportunities.
Learn how to maximize the value of your employee stock options (ESOs) with strategies, tips, and long-term planning. A comprehensive ...
Biopharmaceutical company Atossa Genetics receives Buy rating from H.C. Wainwright, with a new price target of $4.00. The company's promising ...
Goldman Sachs reaffirms Buy rating on ASML Holding NV, expects strong growth in 2025. ASML's impressive order intake and competitive ...
Emeren Group has launched a $10M accelerated stock repurchase program, aiming to increase shareholder value and strengthen its position in ...
Austria considers ending gas contract with Russia to reduce dependency on Russian gas imports. A study will evaluate economic impact ...
Citi initiates coverage on Palmer Square Capital BDC with a Buy rating and $17.00 price target, expressing confidence in the ...
As global shocks and technological advancements reshape the financial landscape, financial firms must embrace advanced technology for compliance or face ...
GCEX partners with Crossover Markets Group for spot cryptocurrency transactions. The collaboration aims to cater to the growing demand for ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.